{"id":55639,"date":"2023-04-10T14:07:33","date_gmt":"2023-04-10T12:07:33","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/"},"modified":"2023-04-10T14:07:33","modified_gmt":"2023-04-10T12:07:33","slug":"new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/","title":{"rendered":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting"},"content":{"rendered":"
\n

IRVINE, Calif.–(BUSINESS WIRE)–#AUA2023<\/a>—CG Oncology<\/a>, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated data will be presented from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck\u2019s anti-PD-1 therapy KEYTRUDA\u00ae<\/sup> (pembrolizumab), for the treatment of patients with non-muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guerin (BCG).<\/p>\n

<\/a><\/p>\n

\nDetails of the oral presentation are as follows:<\/p>\n

\nCORE-001: Phase 2 Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non-Muscle Invasive Bladder Cancer Unresponsive to Bacillus Calmette-Guerin (BCG)
\n
<\/b>Abstract Number: 23-5631
\n
Session: PD13: Bladder Cancer: Non-invasive II
\n
Presenter: Roger Li, M.D., lead study investigator and Urologic Oncologist at Moffitt Cancer Center
\n
Presentation Date & Time: Saturday, April 29, 2023, 8:10-8:20am Central Daylight Time
\n
Location: McCormick Place, S404A<\/p>\n

\nCG Oncology will also be exhibiting at the AUA annual meeting and can be found at booth 3963.<\/p>\n

\nMore information about the study, CORE-001 (NCT04387461), along with other studies sponsored by CG Oncology, can be found at www.clinicaltrials.gov<\/a> or www.cgoncology.com<\/a>.<\/p>\n

\nCG Oncology has previously announced a clinical collaboration with Merck (known as MSD outside the US and Canada) relating to the investigation of cretostimogene grenadenorepvec used in combination with KEYTRUDA\u00ae<\/sup> (pembrolizumab).<\/p>\n

\nAbout Cretostimogene Grenadenorepvec<\/b><\/p>\n

\nCretostimogene grenadenorepvec (CG0070) is an intravesically delivered oncolytic immunotherapy agent in a Phase 3 trial for the treatment of BCG-unresponsive non-muscle invasive bladder cancer. Cretostimogene grenadenorepvec is also in a Phase 2 study in combination with KEYTRUDA\u00ae<\/sup> (pembrolizumab) in the same indication. Other types of bladder cancer are being evaluated with cretostimogene grenadenorepvec in combination with OPDIVO\u00ae<\/sup> (nivolumab).<\/p>\n

\nAbout CG Oncology<\/b><\/p>\n

\nCG Oncology is an oncolytic immunotherapy company focused on developing bladder-saving therapeutics for patients with urologic cancer. At CG Oncology, we see a world where urologic cancer patients can benefit from our innovative therapies to live and work with dignity and an enhanced quality of life. To learn more, visit www.cgoncology.com<\/a>. Follow us on Twitter @cgoncology.<\/p>\n

\nKEYTRUDA\u00ae<\/sup><\/b> is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.<\/p>\n

Contacts<\/b> <\/p>\n

\nInvestor Relations
\n
Bing Kung
\n
Vice President, Business Development
\n
CG Oncology
\n
bd@cgoncology.com<\/a><\/p>\n

\nMedia
\n
Kimberly Ha
\n
KKH Advisors
\n
(917) 291-5744
\n
kimberly.ha@kkhadvisors.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

IRVINE, Calif.–(BUSINESS WIRE)–#AUA2023—CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated data will be presented from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck\u2019s anti-PD-1 therapy … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55639","6":"format-standard","7":"category-industry"},"yoast_head":"\nNew Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"IRVINE, Calif.–(BUSINESS WIRE)–#AUA2023—CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated data will be presented from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck\u2019s anti-PD-1 therapy ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-10T12:07:33+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230410005039\/en\/1758580\/21\/CG_Logo_color_%281%29.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting\",\"datePublished\":\"2023-04-10T12:07:33+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/\"},\"wordCount\":404,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005039\\\/en\\\/1758580\\\/21\\\/CG_Logo_color_%281%29.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/\",\"name\":\"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005039\\\/en\\\/1758580\\\/21\\\/CG_Logo_color_%281%29.jpg\",\"datePublished\":\"2023-04-10T12:07:33+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005039\\\/en\\\/1758580\\\/21\\\/CG_Logo_color_%281%29.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230410005039\\\/en\\\/1758580\\\/21\\\/CG_Logo_color_%281%29.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting - Pharma Trend","og_description":"IRVINE, Calif.–(BUSINESS WIRE)–#AUA2023—CG Oncology, Inc. today announced acceptance of an oral presentation at the American Urological Association (AUA) 2023 Annual Meeting in Chicago, IL from April 28-May 1, 2023. The updated data will be presented from the CORE-001 study, an ongoing Phase 2 clinical trial of cretostimogene grenadenorepvec (CG0070) in combination with Merck\u2019s anti-PD-1 therapy ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-10T12:07:33+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230410005039\/en\/1758580\/21\/CG_Logo_color_%281%29.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting","datePublished":"2023-04-10T12:07:33+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/"},"wordCount":404,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005039\/en\/1758580\/21\/CG_Logo_color_%281%29.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/","url":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/","name":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230410005039\/en\/1758580\/21\/CG_Logo_color_%281%29.jpg","datePublished":"2023-04-10T12:07:33+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230410005039\/en\/1758580\/21\/CG_Logo_color_%281%29.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230410005039\/en\/1758580\/21\/CG_Logo_color_%281%29.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/new-phase-2-data-with-cretostimogene-grenadenorepvec-cg0070-in-combination-with-keytruda-pembrolizumab-in-bcg-unresponsive-nmibc-at-the-aua-2023-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"New Phase 2 Data With Cretostimogene Grenadenorepvec (CG0070) in Combination with KEYTRUDA\u00ae (pembrolizumab) in BCG-Unresponsive NMIBC at the AUA 2023 Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55639","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55639"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55639\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55639"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55639"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55639"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}